Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00090038
Status:
COMPLETED
Last Update Posted:
2009-10-20
First Post:
2004-08-23
Brief Title:
Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkins Lymphoma
Sponsor:
Biogen
Organization:
Biogen
Study Overview
Official Title:
A Multicenter Study to Evaluate the Effect of Rituximab IDEC-102 on Primary Humoral Response Recall Response and Maintenance of Acquired Immunity to Specific Antigens
Status:
COMPLETED
Status Verified Date:
2009-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to provide treatment for patients who have relapsed Non-Hodgkins lymphoma NHL or refractory NHL and to test the immunity of study subjects after receiving four treatments with rituximab
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None